Layer-by-Layer Polymeric Films: A Novel Approach to Buccal GLP-1 Delivery
Buccal delivery offers a promising alternative to oral drug administration by enabling direct systemic absorption and avoiding first-pass metabolism. Multilayer polymeric films represent a promising strategy for the sequential delivery of drug and absorption enhancer in the oral cavity. Here, dual- and triple-layer films were fabricated via slot-die coating, incorporating a GLP-1 receptor agonist (GLP-1-RA) […]
Health Canada warns of fake semaglutide drugs, cites ‘product safety’ risks
Health Canada is warning Canadians of the dangers of buying “fake or unauthorized products” meant to replicate popular GLP-1 drugs such as Ozempic, Rybelsus and Wegovy.
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.
Jelly Roll’s wife says weight-loss drug sent her into ‘worst suicidal depression’
This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255). Bunnie XO, the wife of country singer Jelly Roll, is discussing how a weight-loss medication may have led to her experiencing a “dark” depression. During an episode of […]
Is the 2026 Market Rotation Already Underway? Here’s What Could Lead After the Magnificent 7
Quick Read Magnificent Seven stocks are in the red for 2026 as collective momentum has stalled. Eli Lilly partnered with Nvidia on drug discovery as GLP-1 pills show growth potential. Broadcom trades at 33.3x forward P/E with JP Morgan citing custom silicon momentum. Are you ahead, or behind on retirement? SmartAsset’s free tool can match […]
Medifast’s Q4 Guidance Remains Weak: When Does Growth Return?
Medifast, Inc.’s MED guidance for the fourth quarter of 2025 remains weak, with revenue projected to be between $65 million and $80 million and a loss per share ranging from 70 cents to $1.25. This reflects quite a deterioration from revenues of $119 million and adjusted earnings per share of 10 cents recorded in the […]
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool. Date Thursday, Feb. 6, 2025 at 10 a.m. ET Call participants Chair and Chief Executive Officer — David A. Ricks Chief Financial Officer — Lucas G. Montarce Chief Scientific Officer and President, Lilly Immunology — Dan M. Skovronsky, M.D., Ph.D. President, Lilly Neuroscience — Anne E. White President, Lilly International […]
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
Image source: The Motley Fool. Date Wednesday, Oct. 30, 2024 at 10:00 a.m. ET Call participants Chairman and Chief Executive Officer — David A. Ricks Executive Vice President and Chief Financial Officer — Lucas Montarce Chief Scientific and Medical Officer — Daniel M. Skovronsky President, Lilly Diabetes and Obesity — Patrik Jonsson President, Lilly International […]
Eli Lilly (LLY) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Aug. 7, 2025 at 8:30 a.m. ET Call participants Chairman and Chief Executive Officer — David A. Ricks Chief Financial Officer — Lucas E. Montarce Chief Scientific and Medical Officer — Daniel M. Skovronsky President, Lilly Diabetes and Obesity — Ilya Yuffa Senior Vice President, Global Corporate Affairs — […]
Ozempic Made Weight Loss Therapy Mainstream, But Now It’s Getting Competition
Who would have ever thought that a weight loss injectable would become a household name and pop culture-adjacent phenomenon? Ozempic has become synonymous with modern weight-loss, discussed just as casually as the latest iPhone or sneaker drop. But the era of semaglutide’s unquestioned dominance seems to be slipping with more and more weight loss drugs […]